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Abstract
Bicyclic radester analogues have been synthesized and evaluated for Hsp90 inhibitory activity. These
analogues induce concentration-dependent degradation of Hsp90-dependent client proteins with the
six-membered bicyclic analogues manifesting increased activity versus the five-membered
counterparts.
Keywords
Hsp90; Geldanamycin; Radicicol; Anti-cancer
The 90 kDa heat shock proteins (Hsp90) are well characterized molecular chaperones
responsible for the conformational maturation of nascent polypeptides and the rematuration of
denatured proteins.1,2 Inhibition of Hsp90 disrupts the protein folding process, resulting in
client protein degradation via the ubiquitin-proteasome pathway. Previous studies have
demonstrated that the Hsp90 multiprotein complex prevalent in tumor cells exhibits a higher
affinity for N-terminal ligands than the homodimeric form present in non-transformed cells. It
is well known that malignant cells are highly dependent upon the Hsp90 protein folding
machinery for cell survival due to the over expression of proteins needed for continual growth
in hostile environments.3 Consequently, inhibition of Hsp90 results in combinatorial disruption
of multiple signaling pathways that are essential to tumor cell survival and represents a
promising strategy for the development of therapeutics.4
Hsp90 is an ATP-dependent protein comprised of two nucleotide-binding domains, one of
which is located at the N-terminus and the other at the C-terminus.5 ATP hydrolysis at the N-
terminus provides the requisite energy necessary for folding nascent polypeptides into their
biologically active, three-dimensional conformations. Thus, disruption of this ATPase activity
results in destabilization of the heteroprotein complex, which leads to the subsequent
degradation of clients.3
N-terminal inhibitors of Hsp90 manifest their activity by binding competitively to the N-
terminal ATP-binding site and preventing Hsp90-catalyzed hydrolysis of ATP. To date, several
natural products have been identified as N-terminal inhibitors. Geldana-mycin (GDA)6 and
radicicol (RDC, Fig. 1)6 are two prominent examples previously reported. RDC is the most
potent of these inhibitors in vitro, however, in vivo it is rapidly converted into metabolites that
exhibit little or no affinity for Hsp90.7 In contrast, GDA is less potent than RDC in vitro, but
in cellular assays manifests greater affinity for the Hsp90 heteroprotein complex prevalent in
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malignant cells.3 Although two derivatives of GDA have entered clinical trials for the treatment
of several cancers, toxicity and formulation difficulties remain.
The co-crystal structures of GDA and RDC bound to Hsp908 have been solved and reveal
important binding interactions manifested by these natural products. In contrast to the extended
conformation of GDA found in solution, the natural product binds Hsp90 in a bent, C-shaped
conformation that contains an unusual cis-amide bond. Consequently, it appears the process
of GDA binding to Hsp90 results in an entropic penalty, which has been studied in some detail.
9 In contrast, RDC exists in the same bent conformation bound or unbound to Hsp90, producing
favorable entropy upon binding. As a result of these thermodynamic data, it has been proposed
that GDA analogues that contain conformational rigidity would yield compounds that exhibit
enhanced Hsp90 affinity through minimization of entropic penalties.10–14
Recently, chimeric Hsp90 inhibitors were disclosed in which pharmacophores from both
natural products were combined to provide a novel scaffold. Our laboratory has
developed15–17 this class of chimeric analogues that result from hybridization of the resorcinol
ring of RDC and the quinone of GDA. These compounds bind to the Hsp90 N-terminus and
prevent ATP hydrolysis, similar to the natural products.18 Moreover, radester (Fig. 1) exhibits
more potent ATPase inhibition than GDA.16
Overcoming the entropic barrier associated with the conformational rearrangement observed
by N-terminal ligands upon binding Hsp90 is an important consideration for the development
of new inhibitory scaffolds. Analyses of co-crystal structures of RDC and radester bound to
Hsp90 revealed the ester carbonyl in radester to be more planar than the same moiety in RDC.
The planarity of this carbonyl potentially allows for greater electron delocalization between
the ester carbonyl and the phenols, resulting in an electron rich carbonyl and more acidic
phenols. High electron density at this carbonyl is predicted to be important due to its mediation
of hydrogen bonding interactions with Asp 79, Gly 83 and Thr 171. Thus, inhibitors existing
in a bent conformation that exhibit a planar carbonyl are hypothesized to minimize the entropic
penalty upon binding to Hsp90 and exhibit higher affinity due to increased utilization of the
hydrogen bonding network. Therefore we proposed a series of conformationally constrained
chimeric analogues exhibiting both a bent conformation and conformationally constrained
carbonyls (Fig. 2).
Recently, Duerfeldt et al.19 utilized the chimera radamide as a model to demonstrate that
conformationally constrained cis-amide analogues demonstrate improved affinity. Radester
provides an additional opportunity to probe conformational constraints through manipulation
of the resorcinol motif. Preliminary docking studies which overlay the designed inhibitors 1
and 2 with RDC indicate the carbonyl of the bicyclic analogues to exhibit greater planarity
than RDC (Fig. 3). Defining the plane of the resorcinol as 0° allowed rotation from this plane
to be measured for compounds 1 and 2. As depicted in Figure 3, the radicicol carbonyl exhibits
an angle of ∼45°, whereas 1 exhibits an angle of ∼9°, and compound 2 deviates ∼8°, supporting
the conformational constraint of the carbonyl moieties. Herein, we present the design,
syntheses, and biological evaluation of chimeric Hsp90 inhibitors containing a
conformationally constrained bicyclic ring system.
Retrosynthetically, analogues 1–6 were envisioned to be constructed via an aldol condensation
between nitro-aldehyde 16 and the homologated bicyclic ketones, 13–14 (Scheme 1). Aldehyde
16 was proposed to originate from alcohol 15, which can be prepared in three steps from
commercially available methoxyhy-droquinone. Cyclic ketones 13–14 were to be prepared
from bicyclic ketone compounds, 7–8, which have been previously synthesized from
commercially available 3,5-dimethoxybenzaldehyde.20,21
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Commencing with the synthesis of intermediates 13–14 and 16, as illustrated in Scheme 2,
ketones 7–8 were constructed following known procedures.20,21 Cleavage of the methyl ethers
afforded phenolic compounds 9–10. Resorcinol 9 was obtained by treating 7 with boron
tribromide at −78 °C and 10 was prepared by reaction of 8 with hydrobromic acid in acetic
acid at 110 °C. Treatment of compounds 9–10 with sodium hydride and methoxy methyl
chloride gave the corresponding MOM-protected phenols 11–12 in good yields. Mild
conditions enlisting calcium hypochlorite afforded the chlorinated aromatics, 13–14. Quinone
precursor 16 was prepared by PCC oxidation of alcohol 15, which was readily available via
literature procedures.15
Synthesis of compounds 1–6 was accomplished by following the sequence of reactions
depicted in Scheme 3. Aldol condensation between ketones 13–14 and aldehyde 16 followed
by dehydration of the incipient secondary alcohols enlisting phosphorus oxychloride in
pyridine, provided alkenes 17–18 in good yields. Simultaneous reduction of the nitro and
alkene moieties of 17–18 employing palladium-carbon under a hydrogen atmosphere provided
anilines 19–20. To mimic the amide functionality present in GDA, the aniline was converted
to the corresponding formamide, 21–22, upon treatment with phenylformate. Removal of the
methoxymethyl (MOM) protecting groups in situ with trimethylsilyl iodide resulted in
formation of the corresponding hydroquinones, 1–2,22,23 which were subsequently oxidized
to the desired quinones 3–4 with Frémy's salt (potassium nitrosodisulfonate) in buffered
solution.24,25
Selective reduction of the nitro groups was required to access alkenes 5–6, which was
problematic due to competing redox-sensitive groups (Scheme 3). The best results obtained
utilize zinc metal and acetic acid in dichloromethane, in which case anilines 23–24 were
subsequently converted to the corresponding formamides, 25–26, following reaction with
phenylformate. Quinones 5–6 were then generated utilizing the same oxidation conditions used
to afford 3–4.26,27
Upon completion of their syntheses, chimeric analogues 1–6 were evaluated for their anti-
proliferative activity against MCF7 and SKBr3 breast cancer cell lines. As seen in Table 1, the
six-membered analogues exhibited more potent activity than the corresponding five-membered
analogues, and exhibited similar IC50 values against both cancer cell lines. In contrast, the five-
membered analogues exhibited approximately three-old higher activity against MCF7 cells
than SKBr3 cells.
In order to confirm the growth inhibitory activity manifested by these compounds was a
consequence of Hsp90 inhibition, compounds 1 and 2 were subjected to Western blot analyses.
As expected (Fig. 4), compounds 1 and 2 resulted in dose-dependent client protein degradation.
Similarly, N-terminal inhibitory activity was evidenced by the concentration-dependant
induction of heat shock response as demonstrated by increasing Hsp70 levels. Both, client
protein degradation and heat shock induction at similar concentrations are indicative of Hsp90
N-terminal inhibition.
In conclusion, we have designed, synthesized and evaluated six new conformationally
constrained analogues of radester and tested them against two breast cancer cell lines. Western
blot analyses confirmed Hsp90 inhibition as evidenced by concentration-dependent
degradation of Hsp90 clients and simultaneous induction of heat shock response. In general,
six-membered analogues were found to be more effective than their five-membered
counterparts. However, the activities of these compounds remain comparable to radester,
indicating the introduction of conformationally constrained carbonyls does not play a
significant role in organization of the N-terminal ATP-binding site.
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Known inhibitors of Hsp90.
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Proposed conformationally constrained analogues.
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Overlay of compounds 1 (orange) and 2 (green) with RDC in the Hsp90 N-terminal ATP-
binding domain. The resorcinol plane is depicted as a purple line.
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Western blot analysis (a) for compound 1 and (b) for 2.
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Reagents and conditions: (a) BBr3, −78 °C to rt, 5 h or HBr, AcOH, 110 °C, 48 h; (b) NaH,
DMF, MOMCl, 0°C to rt, 2 h; (c) Ca(OCl)2, acetone, AcOH/H2O (1:10), rt, 2 h; (d) PCC,
DCM, MS (4 Å), rt, 2 h.
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Reagents and conditions: (a) (i) LDA, −78 °C to rt, THF,16, 2 h, (ii) POCl3, pyridine, rt, 6 h;
(b) H2, Pd/C, EtOAc, 6 h; (c) PhOCHO, DCM, 40 °C, 12 h; (d) Zn, AcOH, DCM, rt, 10 min;
(e) NaI, TMSCl, DCM/CH3CN, rt, 1 h; (f) Frémy's salt, acetone, rt, 15 min R = MOM for all
compounds in this scheme.
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1 12.9 ± 2.3 42.1 ± 1.8
2 9.5 ± 0.8 10.5 ± 0.1
3 15.1 ± 0.9 47.3 ± 4.4
4 11.4 ± 0.5 12.8 ± 0.7
5 15.2 ± 0.9 40.8 ± 3.8
6 11.8 ± 0.1 12.5 ± 0.6
GDA 16.1 ± 1.1 nM 15.8 ± 0.9 nM
RDC 47.7 ± 2.6b nM 37.5 ± 4.0b nM
Radester 13.9 ± 1.41c NT
a
IC50 = concentration required to produce 50% inhibition.
b
Obtained from Ref. 19.
c
Obtained from Ref. 16.
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